Zynerba Pharmaceuticals (NASDAQ:ZYNE) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday, March 20th, ValuEngine reports.
A number of other brokerages have also recently issued reports on ZYNE. Zacks Investment Research cut shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, November 21st. Cantor Fitzgerald set a $21.00 price objective on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, December 5th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $14.00.
Shares of NASDAQ ZYNE traded up $0.13 during mid-day trading on